Market Research Logo

Global Transthyretin Amyloidosis (ATTR) Market: Industry Analysis & Outlook (2018-2025)

Global Transthyretin Amyloidosis (ATTR) Market: Industry Analysis & Outlook (2018-2025)

ATTR amyloidosis, A for Amyloid and the TTR is an abbreviation used for the protein “transthyretin.” ATTR amyloidosis is a rare disease, caused by the build-up of abnormal protein deposits in various tissues of the body. Amyloid deposits cause disorder by damaging the structure and the function of the organs where they are found and they can affect almost any part of the body.

There are three different types of ATTR Amyloidosis: Familial Amyloid Polyneuropathy (FAP), which affects the nervous system, often the heart and sometimes the kidneys and eyes. Second is, Familial Amyloid Cardiomyopathy (FAC), which is a hereditary, genetic condition, caused by mutations in the TTR gene resulting in production of the abnormal TTR and the last is, Senile Systemic Amyloidosis (SSA) which is not hereditary and a slowly progressive disease. It is far more prevalent in men than in women. Methods to diagnose ATTR include tissue biopsy, genetic testing and imaging studies of the heart.

Currently, there are no higher efficacy ATTR drugs available in the market, but they are expected to hit the market by 2018. The potential ATTR drug candidates include Patisiran and IONIS-TTRrx. For now, off-label drugs and therapies are employed to counter the progression of ATTR.

The global ATTR market is expected to experience robust growth post the launch of ATTR therapeutic drugs, primarily due to increasing African-American population, increasing health care expenditure and accelerating economic growth. However, the growth of this budding market is is hindered by the stringent regulations, high cost of ATTR drugs, misdiagnosis of ATTR disorder and limitation of clinical trials.

The report “Global ATTR Market: Industry Analysis & Outlook (2018-2025)” analyzes the development of this market, with focus on the U.S. and Europe markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Pfizer Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc. and Prothena Corporation Plc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global ATTR market along with the study of the regional markets.


1. Overview
1.1 Introduction
1.2 Types
Table 1: Types of ATTR Amyloidosis
1.3 Diagnosis
Table 2: Methods for ATTR Diagnosis
1.4 Treatment
Table 3: Current Treatment Therapies for ATTR Amyloidosis
2. Global ATTR Market
2.1 Global ATTR Market Forecast by Patient Volume
Table 4: Global ATTR Market Forecast by Patient Volume (2018-2025)
2.2 Global ATTR Market Forecast by Treated Patient
Table 5: Global ATTR Market Forecast by Treated Patient (2018-2025)
2.3 Global ATTR Market Forecast by Value
Table 6: Global ATTR Market Forecast by Value (2018-2025)
2.4 Global ATTR Market Forecast by Drug Type
Table 7: Global ATTR Market Forecast by Drug Type (2018/2025)
2.4.1 Global Patisiran Market Forecast by Value
Table 8: Global Patisiran Forecast by Value (2018-2025)
2.4.2 Global IONIS-TTRrx Market Forecast by Value
Table 9: Global IONIS-TTRrx Market Forecast by Value (2018-2025)
2.5 Global ATTR Market Value by Region
Table 10: Global ATTR Market Value by Region (2018/2025)
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. ATTR Market Forecast by Patient Volume
Table 11: The U.S. ATTR Market Forecast by Patient Volume (2018-2025)
3.1.2 The U.S. ATTR Market Forecast by Treated Patient
Table 12: The U.S. ATTR Market Forecast by Treated Patient (2018-2025)
3.1.3 The U.S. ATTR Market Forecast by Value
Table 13: The U.S. ATTR Market Forecast by Value (2018-2025)
3.1.4 The U.S. Patisiran Market Forecast by Value
Table 14: The U.S. Patisiran Market Forecast by Value (2018-2025)
3.1.5 The U.S. IONIS-TTRrx Market Forecast by Value
Table 15: The U.S. IONIS-TTRrx Market Forecast by Value (2018-2025
3.2 Europe
3.2.1 Europe ATTR Market Forecast by Patient Volume
Table 16: Europe ATTR Market Forecast by Patient Volume (2018-2025)
3.2.2 Europe ATTR Market Forecast by Treated Patient
Table 17: Europe ATTR Market Forecast by Treated Patient (2019-2025)
3.2.3 Europe ATTR Market Forecast by Value
Table 18: Europe ATTR Market Forecast by Value (2019-2025)
3.2.4 Europe Patisiran Market Forecast by Value
Table 19: Europe Patisiran Market Forecast by Value (2019-2025)
3.2.5 Europe IONIS-TTRrx Market Forecast by Value
Table 20: Europe IONIS-TTRrx Market Forecast by Value (2019-2025)
3.3 ROW
3.3.1 ROW ATTR Market Forecast by Patient Volume
Table 21: ROW ATTR Market Forecast by Patient Volume (2018-2025)
3.3.2 ROW ATTR Market Forecast by Treated Patient
Table 22: ROW ATTR Market Forecast by Treated Patient (2019-2025)
3.3.3 ROW ATTR Market Forecast by Value
Table 23: ROW ATTR Market Forecast by Value (2019-2025)
3.3.4 ROW Patisiran Market Forecast by Value
Table 24: ROW Patisiran Market Forecast by Value (2019-2025)
3.3.5 ROW IONIS-TTRrx Market Forecast by Value
Table 25: ROW IONIS-TTRrx Market Forecast by Value (2019-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rise in African-American Population
Table 26: African-American Population (2012-2016)
4.1.2 Increasing HealthCare Expenditure
Table 27: Global HealthCare Expenditure Per Capita (2012-2016)
4.1.3 Accelerating Economic Growth
Table 28: Global GDP Per Capita (2012-2016)
4.1.4 Development of Drug Therapies
Table 29: Drugs in Development for ATTR (2016)
4.2 Key Trends
4.2.1 Increasing Research & Development Efforts by Companies
Table 30: R&D Expenditure of Companies (2016)
4.2.2 Rising Public Awareness
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 High Cost of ATTR Drugs
4.3.3 Misdiagnosis of ATTR Disorder
4.3.4 Limitation of Clinical Trials
5. Competition
5.1 Global ATTR Market
5.1.1 Revenue Comparison of Key Companies
Table 31: Revenue Comparison of Key Companies (2016)
5.1.2 Market Cap Comparison of Key Companies
Table 32: Market Cap Comparison of Key Companies (2016)
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
Table 33: Pfizer Inc. Revenue by Segments (2016)
6.1.2 Financial Overview
Table 34: Pfizer Inc. Revenue and Net Income (2012-2016)
6.1.3 Business Strategies
Table 35: Pfizer Inc. Acquisitions (2016/2017)
Table 36: Pfizer Inc. Research and Development Expenditure (2014-2016)
6.2 Ionis Pharmaceuticals Inc.
6.2.1 Business Overview
Table 37: Ionis Pharmaceuticals Inc. Revenue by Segments (2016)
6.2.2 Financial Overview
Table 38: Ionis Pharmaceuticals Inc. Revenue and Net Loss (2012-2016)
6.2.3 Business Strategies
Table 39: Ionis Pharmaceuticals Inc. Agreements (2016/2017)
Table 40: Ionis Pharmaceuticals Inc. Research & Development Expenditure (2014-2016)
6.3 Alnylam Pharmaceuticals, Inc.
6.3.1 Business Overview
Table 41: Alnylam Pharmaceuticals, Inc. Drug Development Programs (2016)
6.3.2 Financial Overview
Table 42: Alnylam Pharmaceuticals, Inc. Revenue and Net Loss (2012-2016)
6.3.3 Business Strategies
Table 43: Alnylam Pharmaceuticals Inc. Research & Development Expenses (2014-2016)
6.4 Prothena Corporation Plc.
6.4.1 Business Overview
Table 44: Prothena Corporation Plc. Drug Development Pipeline (2016)
6.4.2 Financial Overview
Table 45: Prothena Corporation Plc. Revenue and Net Loss (2012-2016)
6.4.3 Business Strategies
Table 46: Prothena Corporation Plc. Research & Development Expenditure (2014-2016)
Table 47: Prothena Corporation Plc. Drug Advancement Programs (2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report